HighTower Advisors
VIR icon

HighTower Advisors’s Vir Biotechnology VIR Stock Holding History

HighTower Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,878
Closed -$290K – 3764
2023
Q2 		$290K Sell
11,878
-687
-5% -$17.3K ﹤0.01% 2588
2023
Q1 		$290K Sell
12,565
-5,806
-32% -$148K ﹤0.01% 2479
2022
Q4 		$470K Buy
+18,371
New +$450K ﹤0.01% 2168
2022
Q1 		– Sell
-5,050
Closed -$211K – 3709
2021
Q4 		$211K Sell
5,050
-9,385
-65% -$368K ﹤0.01% 2733
2021
Q3 		$627K Buy
+14,435
New +$625K ﹤0.01% 1928

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HighTower Advisors's VIR Position: Q3 2023 in Review

HighTower Advisors sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 11,878 shares — an estimated $290K sold.

HighTower Advisors first reported a position in VIR in Q3 2021 and held it in 5 quarters. The position peaked at $627K in Q3 2021. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

  • HighTower Advisors reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
  • HighTower Advisors sold 11,878 Vir Biotechnology shares in Q3 2023, an estimated $290K.
  • HighTower Advisors first reported a position in Vir Biotechnology in Q3 2021 and held it in 5 quarters.
  • HighTower Advisors's Vir Biotechnology position peaked at $627K in Q3 2021.
  • 214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on HighTower Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.